Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Gains Board Approval for $495 Million Privatization Offer

publication date: Aug 28, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
The Board of Simcere Pharma has officially accepted a $9.66 go-private offer from its Chairman/Founder Jinsheng Ren and related parties. The transaction price was raised marginally from the original offer of $9.56, made in March when the buyout was first announced. The deal values Simcere at $495 million. Shareholders must still vote on the proposal, but the acquiring syndicate already owns 78% of the shares, so the outcome is not in doubt. More details....

Stock Symbol: (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors